{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:23:41Z","timestamp":1765758221145},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/jcp.0b013e3181723713","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T07:06:01Z","timestamp":1210316761000},"page":"271-278","source":"Crossref","is-referenced-by-count":24,"title":["A Pharmacoeconomic Analysis of Atypical Antipsychotics and Haloperidol in First-Episode Schizophrenic Patients in Taiwan"],"prefix":"10.1097","volume":"28","author":[{"given":"Susan Shur-Fen","family":"Gau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Hu","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Churn-Shiouh","family":"Gau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00019053-200018020-00002","article-title":"Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.","volume":"18","author":"Lindstrom","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort.","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00789054","article-title":"An economic evaluation of schizophrenia-1991.","volume":"30","author":"Wyatt","year":"1995","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/j.1742-1241.2006.01161.x","article-title":"Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications.","volume":"60","author":"Gianfrancesco","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2710.2006.00784.x","article-title":"Treatment of psychosis: 30 years of progress.","volume":"31","author":"De Oliveira","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1359786806071237","article-title":"Symptom domains of schizophrenia: the role of atypical antipsychotic agents.","volume":"20","author":"Burton","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-440X(94)90059-Q","article-title":"Positive and negative symptoms in the psychoses: principal components analysis of items from the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms.","volume":"35","author":"Minas","year":"1994","journal-title":"Compr Psychiatry"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/oxfordjournals.schbul.a007024","article-title":"Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes.","volume":"29","author":"Mojtabai","year":"2003","journal-title":"Schizophr Bull"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: a problem that will not go away.","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics.","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","article-title":"Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.","volume":"66","author":"Dossenbach","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.jcp.0000231536.79175.cd","article-title":"Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications.","volume":"26","author":"Gianfrancesco","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/59.suppl_8.S5","article-title":"Antipsychotic therapy: a pharmacoeconomic perspective.","volume":"59","author":"Rey","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.","volume":"163","author":"Rosenheck","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2001-15179","article-title":"Atypical antipsychotics in bipolar and schizoaffective disorders.","volume":"34","author":"Brown","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4088\/JCP.v60n1208","article-title":"Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.","volume":"60","author":"Coley","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1176\/appi.ps.53.7.891","article-title":"One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.","volume":"53","author":"Patel","year":"2002","journal-title":"Psychiatr Serv"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1176\/appi.ajp.158.2.266","article-title":"Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.","volume":"158","author":"Rabinowitz","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1176\/appi.ps.55.12.1427","article-title":"Use of health care services and costs of psychiatric disorders among National Health Insurance enrollees in Taiwan.","volume":"55","author":"Chien","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R24-4-20210128","first-page":"138","article-title":"Classification of drugs using the ATC system (anatomic, therapeutic, chemical classification) and the latest changes.","volume":"58","author":"Skrbo","year":"2004","journal-title":"Med Arh"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.schbul.a033377","article-title":"Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.","volume":"25","author":"Bellack","year":"1999","journal-title":"Schizophr Bull"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00023210-200216070-00004","article-title":"Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.","volume":"16","author":"Csernansky","year":"2002","journal-title":"CNS Drugs"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1192\/bjp.171.6.509","article-title":"Costs of schizophrenia.","volume":"171","author":"Knapp","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archpsyc.57.10.987","article-title":"Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.","volume":"57","author":"Essock","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","article-title":"Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.","volume":"67","author":"Valenstein","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr Serv"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1176\/ajp.2006.163.12.2047","article-title":"Clinical trial-based cost-effectiveness analyses of antipsychotic use.","volume":"163","author":"Polsky","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.4088\/JCP.1006e12","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.","volume":"67","author":"Green","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"suppl 19","key":"R36-4-20210128","first-page":"9","article-title":"Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome.","volume":"59","author":"DeQuardo","year":"1998","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3181723713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T06:37:06Z","timestamp":1684391826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200806000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181723713","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}